MHO M/I Homes, Inc.
M/I Homes, Inc., together with its subsidiaries, engages in the construction and sale of single-family residential homes in Ohio, Indiana, Illinois, Minnesota, Michigan, Florida, Texas, North Carolina, and Tennessee. The company operates through Northern Homebuilding, Southern Homebuilding, and Financial Services segments. It also designs, constructs, markets, and sells single-family homes and attached townhomes to first-time, move-up, empty-nester, multi-generational, and luxury homebuyers under the M/I Homes brand name. In addition, the company purchases undeveloped land to develop into developed lots for the construction of single-family homes, as well as for sale to others. Further, it originates and sells mortgages; and serves as a title insurance agent by providing title insurance policies, examination, and closing services to purchasers of its homes. The company was formerly known as M/I Schottenstein Homes, Inc. and changed its name to M/I Homes, Inc. in January 2004. M/I Homes, Inc. was founded in 1976 and is based in Columbus, Ohio.…
Industry Peers
Residential ConstructionKey Statistics
About M/I Homes (NYSE: MHO)
›
M/I Homes (NYSE: MHO) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Residential Construction industry, part of the Consumer Cyclical sector, and reports about 1,801 employees.
The shares were at 121.38 USD on 19 November 2026, down 5.7% over 52 weeks. Its 52-week range is 113.67 USD to 163.50 USD: the price is 25.8% below the high and 6.8% above the low.
At a market capitalisation of 3.04B USD, it trades at 11.5 times trailing earnings and 10.8 times forward earnings. The median trailing P/E of its 20 largest Residential Construction peers is 13.7, a discount of 16% for MHO.
M/I Homes reports return on equity of 12.7%, an operating margin of 9.1% and revenue down 4.9% year over year.
Its debt exceeds its cash by 375.79M USD, a debt-to-equity ratio of 0.33. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 3 analysts cover the stock, with an average rating of Buy; their mean price target of 156.67 USD is 29.1% above the current price. The next earnings report is expected on 27 January 2027.